drugset / Trial / NCT05728736

Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau

NCT05728736

RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study will look at the effects of lemborexant on Alzheimer's disease biomarkers found in the cerebrospinal fluid (CSF) and blood in individuals who are poor sleepers

Timeline

Start
2023-03-01
Primary completion
2023-09-27
Completion
2023-10-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Lemborexant Small molecule 25 mg

Indications